摘要
目的:体外建立人肺腺癌细胞多药耐药细胞系。方法:以阿霉素(adriamycin,ADM)为诱导药,人肺腺癌细胞系(SPCA1)为诱导对象,逐步增加ADM药物浓度进行诱导,以一定浓度ADM培养46周后,光镜观察细胞形态,采用MTT法检测细胞耐药指数(RF),并同时对长春地辛、足叶乙甙、顺铂、5氟脲嘧啶、紫杉醇、ADM6种药物进行交叉耐药检测。结果:SPCA1/ADM形态不规则,SPCA1/ADM对ADM的RF为11.3,同时对长春地辛、足叶乙甙、顺铂、5氟脲嘧啶、紫杉醇5种抗癌药物有不同程度的耐药性。结论:建立了相对稳定多药耐药细胞系SPCA1/ADM,可用于多药耐药性机制及逆转的研究。
Objective: To establish the multi-drug resistance of human lung cancer cell line (SPC-A-1/ADM) in vitro. Methods: As doxorubicin was inductive drug, the human lung cancer cell line(SPC-A-1)was gradually added to doxorubicin density. After cultivated for forty-six weeks,we observed the status of the SPC-A-1/ADM. The drug resistance of SPC-A-1/ADM to doxorubicin was detected by MTT assay,and the coefficient drug resistances of it to those of vindesine salphate,etoposide,cisplatin,fluorouracil,paclitaxel were coordinatly detected. Results:The SPC-A-1/ADM was abnormal. As compared with SPC-A-1,the drug resistance of SPC-A-1/ADM to doxorubicin was 11.3 times,and the coefficient drug resistance of it to vindesine salphate,etoposide,cisplatin,fluorouracil,paclitaxel were in different degree. Conclusion:The SPC-A-1/ADM has been established, and it could be used to study the mechanism of multi-drug resistance in future.
出处
《新疆医科大学学报》
CAS
2005年第6期540-542,共3页
Journal of Xinjiang Medical University
基金
自治区卫生厅青年科技人才专项科研基金资助项目(199903)
关键词
人肺腺癌细胞系
多药耐药
阿霉素
诱导
human lung cancer cell line (SPC-A-1)
multi-drug resistance
adriamycin (doxorubicin, ADM)
inductive
